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Abstract
Background: Carbonic anhydrase (CA) isozymes may have an important role in cancer
development. Some isozymes control pH homeostasis in tumors that appears to modulate the
behaviour of cancer cells. CA XIII is the newest member of the CA gene family. It is a cytosolic
isozyme which is expressed in a number of normal tissues. The present study was designed to
investigate CA XIII expression in prospectively collected colorectal tumor samples.
Methods: Both neoplastic and normal tissue specimens were obtained from the same patients.
The analyses were performed using CA XIII-specific antibodies and an immunohistochemical
staining method. For comparison, the tissue sections were immunostained for other cytosolic
isozymes, CA I and II.
Results: The results indicated that the expression of CA XIII is down-regulated in tumor cells
compared to the normal tissue. The lowest signal was detected in carcinoma samples. This pattern
of expression was quite parallel for CA I and II.
Conclusion: The down-regulation of cytosolic CA I, II and XIII in colorectal cancer may result
from reduced levels of a common transcription factor or loss of closely linked CA1, CA2 and CA13
alleles on chromosome 8. Their possible role as tumor suppressors should be further evaluated.
Background
Carbonic anhydrases (CAs) are a growing family of zinc-
containing metalloenzymes that have an important role
in maintaining the pH homeostasis by catalysing the
reversible hydration of carbon dioxide, CO2 + H2O ↔
HCO3 - + H+. This family includes at least twelve enzymat-
ically active isozymes, whose subcellular localization, tis-
sue distribution and kinetic properties differ. Five of the
isozymes are cytosolic (CA I, II, III, VII and XIII), four are
membrane associated (CA IV, IX, XII and XIV), two are
mitochondrial (CA VA and VB) and one is a secretory
form (CA VI) [1-6]. CAs contribute to several important
biological functions, such as respiration, bone resorption,
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ebrospinal fluid and gastric acid [1,7].
It is typical for solid tumors to create a pH gradient
between the intracellular and extracellular compartments
by acidifying the surrounding tissue to lower pH value
than in adjacent normal tissue. Extracellular acidification
has been associated with many tumor progression effects,
such as loss of intercellular adhesion, increased metastasis
and migration, increased rate of mutations and reduced
DNA repair and upregulation of growth factors and pro-
teases [4]. In order to maintain the pH gradient, tumor
cells express ion transport proteins, including vacuolar
H+-ATPase, Cl-/HCO3 - exchanger and Na+/H+ exchanger
[8,9]. Previously, lactic acid has been considered a major
source of acidity in tumors [4]. More recent studies have
indicated, however, that carbon dioxide also makes a sig-
nificant contribution to the tumor acidity, which strongly
implies to the importance of CA activity in oncogenesis.
This hypothesis has been indirectly supported by the
recent findings that several CA inhibitors may suppress
the invasion capacity of malignant cell lines [4].
CA XIII is a novel enzyme, which is expressed in several
human tissues including salivary glands, kidney, small
intestine, colon, uterus and testis. Modelling of CA XIII
protein revealed that is a globular molecule, and it has the
highest (about 60%) identity with cytosolic isozymes CA
I, II and III. Therefore, CA XIII is clustered as cytosolic/
intracellular isoform. In the previous report, we described
the production of recombinant mouse CA XIII protein,
which was used in detailed activity and inhibition studies
[2,10]. CA XIII demonstrated moderate CA catalytic activ-
ity with kcat/Km of 4.3 × 107 M-1s-1, and kcat of 8.3 × 104 s-1
at 25°C and pH 7.5 [2]. Interestingly, CA XIII showed
unique inhibitory properties compared to CA I, II and IX
[10]. The clinically used sulfonamides including aceta-
zolamide, methazolamide, dichlorophenamide, and dor-
zolamide demonstrated potent CA XIII inhibition, with
Ki's in the range of 17–23 nM. Another group of inhibi-
tors, the sulfanilyl-derived compounds, obtained by reac-
tion of aminosulfonamides with 4-acetamido-
benzenesulfonyl chloride showed very potent CA XIII
inhibitory properties, with Ki's in the range of 1.3–2.4 nM,
whereas these compounds were generally much less effec-
tive as inhibitors of isozymes I, II, and IX.
Different CA isozymes have become attractive targets in
studies aimed at molecular mechanisms of carcinogene-
sis. CA IX and XII have been clearly associated with certain
types of cancer [11-21]. Also cytosolic isozymes CA I and
II have been investigated in some tumors including color-
ectal cancer [22,23]. Since there was no previous data on
CA XIII in tumors, we collected a series of colorectal neo-
plasias and adjacent normal tissues, and analyzed them
by an immunohistochemical staining method for the
expression of this novel isozyme.
Methods
Antibodies
The rabbit anti-mouse/human CA XIII antibody has been
described in a recent article [2]. It was raised against a syn-
thetic peptide (AC-) DGDQQSPIEIKTKEC (-COOH). The
affinity and specificity of the antibody was confirmed by
ELISA titre analysis, western blotting and immunohisto-
chemistry. In immunohistochemical staining, CA XIII has
shown a distinctly different distribution pattern com-
pared to the localization of CA I or II [2]. This finding
indicates that the anti-CA XIII antibody does not cross-
react with CA I or II under the present staining conditions.
Rabbit antisera against human CA I and II have been pro-
duced and characterized earlier [24].
Immunohistochemistry
The normal tissue samples from the large intestine and the
corresponding benign and/or malignant neoplastic sam-
ples were prospectively collected at Oulu University Hos-
pital (Oulu, Finland). The normal samples were excised
separately 20 centimeters proximally from the tumor
resection site. The study was approved by the Ethics Com-
mittee of Oulu University Hospital and performed accord-
ing to the guidelines of the Declaration of Helsinki.
32 distinct areas (both normal tissue and pathological
lesions) of the human colorectal mucosa were examined
from 12 patients. They consisted of 11 separate samples of
histologically normal human colon or rectum and 17
colorectal lesions, including 6 adenomas and 11 adeno-
carcinomas. In 4 samples, normal tissue was found adja-
cent to the neoplasm and was included in the analyses.
The grade of dysplasia was moderate in 3 and grave in 3
adenomas. The group of 11 malignant colorectal tumors
consisted of 4 well-differentiated and 4 moderately differ-
entiated adenocarcinomas, and 3 adenocarcinomas with a
mucinous component. It should be noted that each
patient had either one or more (1–3) lesions which were
analyzed.
The specimens were fixed in Carnoy's fluid (absolute eth-
anol + chloroform + glacial acetic acid 6:3:1) for 6 hours.
The samples were then dehydrated, embedded in paraffin
in a vacuum oven at 58°C, and sections of 5 µm were
placed on gelatine-coated microscope slides The CA iso-
zymes were immunostained by the biotin-streptavidin
complex method, employing the following steps: (a) pre-
treatment of the sections with undiluted cow colostral
whey (Biotop Oy, Oulu, Finland) for 30 min and rinsing
in phosphate-buffered saline (PBS), (b) incubation for 1
hr with primary antibodies diluted 1:100 in 1% bovine
serum albumin -PBS (BSA-PBS), (c) incubation for 1 hrPage 2 of 7
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ries inc., South San Fransisco, CA) diluted 1:300 in 1%
BSA-PBS, (d) incubation for 30 min with streptavidin-
horseradish peroxidase (HRP) conjugate (Zymed labora-
tories) diluted 1:750 in PBS and (e) incubation for 2 min
in DAB solution containing 4,5 mg 3,3'-diaminobenzi-
dine tetrahydrochloride (Fluka, Buchs, Switzerland) in
7,5 ml PBS + 2,5 µl 30% H2O2. The sections were washed
three times for 10 min in PBS after incubation steps b and
c, and four times for 5 min in PBS after step d. All the incu-
bations and washings were carried out at room tempera-
ture. The sections were finally mounted in Neo-Mount
(Merck, Darmstadt, Germany). The stained sections were
examined and photographed with Zeiss Axioskop 40
microscope (Carl Zeiss, Göttingen, Germany). The inten-
sity of immunostaining was scored on a scale of 0 to 3 as
follows: 0, no reaction; 1, weak reaction; 2, moderate reac-
tion; 3, strong reaction.
Results and discussion
Carbonic anhydrase XIII is a recently discovered enzyme,
which is expressed in a number of different mammalian
tissues. Structural modelling revealed that it is most
closely related to cytosolic isozymes, CA I, II, and III with
about 60% sequence identity, and therefore, this isozyme
was clustered to the group of cytosolic/intracellular iso-
forms. Even though the previous paper described the dis-
tribution of CA XIII in several normal tissues, no data has
been published to date on its expression in neoplastic tis-
sues. To get a better insight into the changes in the expres-
sion levels that occur during the development of
neoplasia, we analyzed both normal and pathological
colorectal specimens from the same individuals.
Figures 1 and 2 show some images of CA XIII immunos-
taining in the colorectal tumors and normal mucosa.
Reactions for CA I and II are shown for comparison. The
immunostaining scoring results are shown in Figure 3.
The results indicated that CA XIII immunoreactions gen-
erally follow a similar pattern with CA I and II, i.e. the sig-
nals became weaker along with increasing dysplasia and
malignancy grades. There were a few exceptions, and par-
ticularly, CA II expression was relatively high in adenocar-
cinomas with a mucinous component, while CA I and XIII
were decreased like in other adenocarcinomas (Fig. 2).
Previous studies have indicated that CA IX and XII are
overexpressed in certain tumors, including colorectal ade-
nomas and carcinomas [18,23]. They have been function-
ally linked to extracellular acidification in tumors that
appears to regulate the invasive behaviour of tumor cells.
Consequently, expression of CA IX has been associated
with poor prognosis of some malignancies [19,20,25,26].
Based on the present and previous results [23], cytosolic
isozymes I, II, and XIII do not probably play a significant
role in the regulation of pH in tumors. Instead, they may
be important factors for the normal intestinal physiology.
This suggestion raises an important question why at least
three cytosolic isozymes are expressed in the normal
colorectal mucosa. Even though we cannot answer to this
question at this stage, it is of interest that these CAs repre-
sent isoforms with different kinetic or inhibitory proper-
ties. CA II exhibits the highest and CA I and CA XIII
moderate carbon dioxide hydratase activities [2]. Because
of different biochemical characteristics, it is unlikely that
all these isozymes could contribute to the same pH regu-
lation process. If this was the case, one could suggest that
the enzymes with low or moderate activities should repre-
sent some sort of "junk" proteins in the proteome. How-
ever, there are other possible explanations which could be
considered more sound in a biological system. First, sev-
eral CA isozymes have emerged during evolution, because
CA enzymatic activity is required for very fundamental
reactions in the body. If one isozyme was functionally
defective, the others could compensate the missing one.
These compensatory mechanisms would partly explain
why different CA deficiencies typically produce no or only
mild phenotypic changes [27-29].
Another possible role of cytosolic CAs could be linked to
a hypothetical tumor suppressor function. It is notable
that CA1, CA2 and CA13 genes are closely linked locating
in the q arm of chromosome 8. Simultaneous loss of
expression could result from a deletion or point muta-
tions within regulatory regions or alleles specifying these
genes. The down-regulation could also result from
reduced levels of a common transcription factor. Regard-
less of the mechanism, three cytosolic CA isozymes are
affected in colorectal tumors, and it would be tempting to
propose that normal CA I, II and/or XIII proteins could
have a tumor suppressor function in epithelial cells, and
deletion of those alleles could be an important factor in
the cascade of events contributing to colorectal carcino-
genesis. Even though colorectal cancer has been associ-
ated with gain of chromosome 8q in a number of previous
studies, and no losses have been reported [30-33], there is
some evidence that 8q21 contains a yet unidentified
tumor suppressor gene [34,35]. However, larger sets of
tumors will be required to define explicitly, whether these
CA genes are involved in genetic alterations of colorectal
tumors.
Conclusion
CA XIII expression was clearly decreased in colorectal
tumors compared to the normal tissue in a pattern similar
to CA I and II. Loss of expression of closely linked CA1,
CA2 and CA13 genes may result from reduced levels of a
transcription factor or loss of alleles specifying these
genes.Page 3 of 7
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BMC Cancer 2005, 5:41 http://www.biomedcentral.com/1471-2407/5/41Immunohistochemical staining of CA I, II and XIII in the normal colonic mucosa and tumorsFigure 1
Immunohistochemical staining of CA I, II and XIII in the normal colonic mucosa and tumors. The samples of nor-
mal mucosa, adenoma (grave dysplasia) and well differentiated adenocarcinoma were collected from one patient. The strongest 
immunoreaction is located in the enterocytes of the normal mucosa (arrows). Original magnification × 200.Page 4 of 7
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BMC Cancer 2005, 5:41 http://www.biomedcentral.com/1471-2407/5/41CA expression in the normal colonic mucosa and adenocarcinoma with a mucinous componentFigure 2
CA expression in the normal colonic mucosa and adenocarcinoma with a mucinous component. CA II staining 
intensity remained at a relatively high level in the carcinoma sample (arrows), whereas the intensities for other isozymes were 
decreased compared to the normal epithelium.Page 5 of 7
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